Race Oncology

Innovative lead drug

Solving real problems in cancer care

Experienced management and board

Growing market opportunity

Dr Daniel Tillett

Dr Peter Smith

Dr Serge Scrofani

Dr Megan Baldwin

Why Invest

Updates

Announcements

Home

Inter

We invite shareholders and interested parties to engage with the Race Oncology leadership team via our interactive Investor Hub.

Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well- characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity. 

Bisantrene (RC220) is a clinically and commercially attractive formulation with a long IP life.

ASX Announcements

Presentation